Sutro Biopharma (STRO) to Post Earnings on Thursday

Sutro Biopharma (NASDAQ:STRO) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Sutro Biopharma to announce earnings of ($2.2204) per share and revenue of $11.7760 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings data on Thursday, May 14th. The company reported ($2.94) earnings per share for the quarter, missing the consensus estimate of ($2.74) by ($0.20). The business had revenue of $14.52 million for the quarter, compared to analysts’ expectations of $8.89 million. On average, analysts expect Sutro Biopharma to post $-9 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Sutro Biopharma Trading Up 2.3%

Sutro Biopharma stock opened at $25.67 on Wednesday. Sutro Biopharma has a 1-year low of $7.15 and a 1-year high of $43.85. The firm has a market capitalization of $425.35 million, a price-to-earnings ratio of -2.33 and a beta of 1.55. The firm’s fifty day moving average price is $27.56 and its two-hundred day moving average price is $25.53.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. State of Tennessee Department of Treasury bought a new position in Sutro Biopharma during the fourth quarter valued at approximately $86,000. Opaleye Management Inc. purchased a new stake in Sutro Biopharma during the 4th quarter valued at $2,206,000. Balyasny Asset Management L.P. purchased a new position in shares of Sutro Biopharma in the fourth quarter worth $2,662,000. ADAR1 Capital Management LLC bought a new stake in Sutro Biopharma in the 4th quarter worth about $776,000. Finally, Jane Street Group LLC purchased a new position in shares of Sutro Biopharma during the fourth quarter valued at approximately $265,000. 96.99% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on STRO. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a report on Friday, May 8th. Truist Financial assumed coverage on Sutro Biopharma in a research note on Thursday, June 11th. They set a “buy” rating and a $50.00 price target for the company. HC Wainwright boosted their price objective on Sutro Biopharma from $28.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Barclays started coverage on Sutro Biopharma in a research note on Thursday, May 28th. They issued an “overweight” rating and a $56.00 price objective for the company. Finally, Wall Street Zen lowered Sutro Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, June 14th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Sutro Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $52.44.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.